CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The TRIAD project seeks to develop a selective antagonist of CD28 to treat autoimmune diseases by specifically targeting the immune response. This approach aims to suppress harmful immune activity while preserving regulatory functions to restore tolerance in conditions like rheumatoid arthritis and type 1 diabetes.
The TRIAD, Tolerance Restoration In Autoimmune Disease, consortium provides an innovative strategy to autoimmune diseases (AID) therapy, based on antibody approach with a well established mechanism of action.
The main objective is the evaluation of a selective antagonist of CD28 to prevent, treat and/or cure some AIDs in preclinical models including rheumatoid arthritis, multiple sclerosis, type 1 diabetes, psoriasis, uveitis and arteriosclerosis.The concept is based on rather than suppressing t…
EFFIMUNE SAS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Oxford
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
